In-house bioequivalence testing to be acceptable, KFDA says
Published: 2006-11-17 06:59:00
Updated: 2006-11-17 06:59:00
The government will accept drug maker's in-house bioequivalence testing only, and the acceptable number of the joint bioequivalence testing items will be limited to five, the Korea Food and Drug Administration (KFDA) said on November 15.
According to the newly revised pharmaceutical law that w...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
